Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
ALISO VIEJO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it will host a conference call and a live Internet webcast along with...
MAA successfully validated by EMEA ALISO VIEJO, Calif., Dec. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that the U.S. Food and Drug...
CHICAGO, Nov. 24 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for AIG, BIDU, PPG, JEF, and VRX. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE:VRX) today announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for...
- Revenue up 31%, 45% at constant exchange rates - GAAP EPS $0.45, Cash EPS $0.58 - GAAP Cash Flow from Operations $52 million; Adjusted Cash Flow from Operations $65 million - Increased guidance...
AIM 01 October 2009 ? NOTICE (686) 01/10/2009 7:00am CANCELLATION OF ADMISSION OF SECURITIES TO TRADING ON AIM VECTRIX CORPORATION Trading on AIM for the under-mentioned securities have been...
-- Dr. LeWinn's is the highest selling skincare brand in Australian pharmacies -- Hissyfit and Revitanail/Renunail brands also included in acquisition ALISO VIEJO, Calif., Sept. 30...
Vectrix Corporation 29 September 2009 ? Date: September 28, 2009 On behalf of: Vectrix Corporation ("Vectrix" or "the Company") For immediate release Middletown, R.I. - Vectrix Corporation...
-- U.S. submission expected on or before October 23, 2009 -- EMEA submission expected on October 30, 2009 -- Modified Release Phase I clinical study commencing in September ALISO VIEJO, Calif...
ALISO VIEJO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that J. Michael Pearson, the Company's chairman and chief executive...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
